MedTrace Logo

Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial

NCT06007222 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-09-23

No results posted yet for this study

Summary

Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.

Non-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.

Conditions

  • Aortic Stenosis
  • TAVI(Transcatheter Aortic Valve Implantation)
  • Aspirin
  • DAPT(Dual Antiplatelet Therapy)
  • SAPT(Single Antiplatelet Therapy)

Interventions

DRUG

Aspirin group

Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.

DRUG

Non-antithrombotic group

No antithrombotic agents will be administered after randomization until the end of the study period.

Sponsors & Collaborators

  • OCEAN-SHD Study Group

    lead OTHER

Principal Investigators

  • Yosuke Sawa · EPS Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-06
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06007222 on ClinicalTrials.gov